Condition: Breast Cancer · Cardiotoxicity · Cardiomyopathies · Sponsor: National University of Ireland, Galway, Ireland
In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime. There is evidence that female breast cancer survivors are more likely to die of cardiovascular disease than their age-matched counterparts. This research is focused on evaluating pathways for identifying, managing, and overcoming side effects of cancer therapies that can negatively impact quality-of-life and overall outcomes for women during and after cancer treatment. The Cardio-oncology research team at GUH plan to capitalize on their expertise in both cancer care and cardiology to develop a care pathway for cancer patients who are at increased risk of developing heart disease.
This description comes directly from the study's public registry record.
Osama Soliman, MBBCh, PhD · +35391493781 · osama.soliman@nuigalway.ie
Aoife Lowery, MBBCh, PhD · aoife.lowery@nuigalway.ie
Always discuss trial participation with your own doctor first.
| Galway University Hospital | Galway, Ireland | Recruiting |
| Galway Clinic | Galway, Ireland | Recruiting |
| Mayo University Hospital | Mayo, Ireland | Recruiting |
| Sligo General Hospital | Sligo, Ireland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05921279